A Budget Impact Model for the Introduction of Bevacizumab for the Treatment of Newly Diagnosed Glioblastoma Multiforme in the UK von Scola, A.M, Lock, K, Ngoh, C.A

Volltext

Task-Based Versus Case-Based Analysis of Time Outcomes in Multi-Country Time and Motion (T&M) Studies: Methodological Considerations and Application von De, Cock E, Kritikou, P, Tao, S, Ngoh, C.A

Volltext

Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies P... von Rule, S, Briones, J, Smith, R, Theodore, Oklota C, Ngoh, C.A, Osborne, S, Capochiani, E, Rummel, M

Volltext

Simulation and Comparison of Progression-Free Survival (Pfs) Among Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Therapy von Chouaid, C, Walzer, S, Lister, J, Gultyaev, D, Vergnenegre, A, de Marinis, F, Meng, J, de Castro, J, Crott, R, Kleman, M, Ngoh, C.A

Volltext

PCN66 A Cost and Outcomes Analysis of Bevacizumab plus Folfiri Versus Cetuximab Plus Folfiri for the Treatment of First-Line Metastatic Colorrectal Cancer Patients from the Brazili... von Caponero, R, Santos, E.A.V, Buschinelli, C.T, Ferracini, M, Ngoh, C.A

Volltext

Economic Impact of Including Sequential Bevacizumab for the Treatment of Patients with Kirsten Ras Wild Type Unresectable Metastatic Colorectal Cancer in Four Latin American Countr... von Rautenberg, T, Tournier, C, Ngoh, C.A, Arnaiz, F, Carrizo, M, Lewi, D, Garcia, A, Mitre, N, Painemal, C, Parada, L, Bárbosa, D, Rosselli, D, Alva, M, Torrecillas, L

Volltext

PCN45 - A Budget Impact Model for the Introduction of Bevacizumab for the Treatment of Newly Diagnosed Glioblastoma Multiforme in the UK von Scola, A.M, Lock, K., Ngoh, C.A.

Volltext

PRM194 - Task-Based Versus Case-Based Analysis of Time Outcomes in Multi-Country Time and Motion (T&M) Studies: Methodological Considerations and Application von De, Cock E., Kritikou, P., Tao, S., Ngoh, C.A.

Volltext

PSY89 - Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii S... von Rule, S., Briones, J., Smith, R., Theodore, Oklota C., Ngoh, C.A., Osborne, S., Capochiani, E., Rummel, M.

Volltext

PCN13 - Simulation and Comparison of Progression-Free Survival (Pfs) Among Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Receiving Sequential Therapy von Chouaid, C., Walzer, S, Lister, J., Gultyaev, D., Vergnenegre, A., de Marinis, F., Meng, J., de Castro, J., Crott, R., Kleman, M., Ngoh, C.A.

Volltext

PCN11 - Economic Impact of Including Sequential Bevacizumab for the Treatment of Patients with Kirsten Ras Wild Type Unresectable Metastatic Colorectal Cancer in Four Latin America... von Rautenberg, T., Tournier, C., Ngoh, C.A., Arnaiz, F., Carrizo, M., Lewi, D., Garcia, A., Mitre, N., Painemal, C., Parada, L., Bárbosa, D., Rosselli, D., Alva, M., Torrecillas, L.

Volltext